Compounds of reverse turn mimetics and the use thereof

Details Compounds of reverse turn mimetics and the use thereof Compounds of reverse turn mimetics and the use thereof

2008-10-15

2011-12-20

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S243000

Reexamination Certificate

active

08080657

ABSTRACT:
Conformationally constrained compounds that are novel and mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins and having bicyclic framework are disclosed, as well as their prodrugs. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. The invention also relates to a use of such compounds for the preparation of a medicament for treating or preventing cancer including an acute myeloid leukemia.

REFERENCES:
patent: 5440013 (1995-08-01), Kahn
patent: 5475085 (1995-12-01), Kahn
patent: 5618914 (1997-04-01), Kahn
patent: 5670155 (1997-09-01), Kahn
patent: 5672681 (1997-09-01), Kahn
patent: 5693325 (1997-12-01), Kahn
patent: 5710245 (1998-01-01), Kahn
patent: 5840833 (1998-11-01), Kahn
patent: 5859184 (1999-01-01), Kahn et al.
patent: 5929237 (1999-07-01), Kahn
patent: 6013458 (2000-01-01), Kahn et al.
patent: 6020331 (2000-02-01), Kahn
patent: 6117896 (2000-09-01), Qabar et al.
patent: 6184223 (2001-02-01), Kahn et al.
patent: 6245764 (2001-06-01), Kahn et al.
patent: 6294525 (2001-09-01), Stasiak et al.
patent: 6372744 (2002-04-01), Qabar et al.
patent: 6413963 (2002-07-01), Kahn et al.
patent: 6440955 (2002-08-01), Stasiak et al.
patent: 6548500 (2003-04-01), Kahn et al.
patent: 6762185 (2004-07-01), Moon et al.
patent: 7232822 (2007-06-01), Moon et al.
patent: 7531320 (2009-05-01), Kahn et al.
patent: 7563825 (2009-07-01), Kahn
patent: 7566711 (2009-07-01), Moon et al.
patent: 7576084 (2009-08-01), Moon et al.
patent: 7585862 (2009-09-01), Moon et al.
patent: 7671054 (2010-03-01), Moon et al.
patent: 2001/0039274 (2001-11-01), Kahn et al.
patent: 2002/0022620 (2002-02-01), Kahn et al.
patent: 2002/0065416 (2002-05-01), Stasiak et al.
patent: 2002/0068695 (2002-06-01), Scolastico et al.
patent: 2003/0021773 (2003-01-01), Moroder et al.
patent: 2003/0027819 (2003-02-01), Qabar et al.
patent: 2003/0105103 (2003-06-01), Golebiowski et al.
patent: 2004/0072831 (2004-04-01), Moon et al.
patent: 2005/0059628 (2005-03-01), Kahn et al.
patent: 2007/0128669 (2007-06-01), Kahn
patent: 2007/0129353 (2007-06-01), Kahn
patent: 2384126 (2001-03-01), None
patent: WO 94/03494 (1994-02-01), None
patent: WO 97/15577 (1997-05-01), None
patent: WO 98/05333 (1998-02-01), None
patent: WO 98/49168 (1998-11-01), None
patent: WO 01/00210 (2001-01-01), None
patent: WO 01/16135 (2001-03-01), None
patent: WO 03/006447 (2003-01-01), None
patent: 03/031448 (2003-04-01), None
patent: WO 2004/072076 (2004-08-01), None
patent: WO 2004/072077 (2004-08-01), None
patent: 2004/093828 (2004-11-01), None
patent: 2005/116032 (2005-12-01), None
Cheng et al., “Effects of Renal Function on Recainam Pharmacokinetics and Pharmacodynamics,”Clinical Pharmacology&Therapeutics57(5):492-498, May 1995.
Dresser et al., “Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition,”Clinical Pharmacokinetics38(1):41-57, 2000.
Eichler et al., “Cyclic Peptide Template Combinatorial Libraries: Synthesis and Identification of Chymotrypsin Inhibitors,”Peptide Research7(6):300-307, 1994.
Hoffman et al., “The proto-oncogene c-mycin hematopoietic development and leukemogenesis,”Oncogene21:3414-3421, 2002.
Jung et al., “Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof,” U.S. Appl. No. 12/759,854, filed Apr. 14, 2010, 59 pages.
Kahn et al., “Reverse-turn mimetics and method relating thereto,” U.S. Appl. No. 09/976,470, filed Oct. 12, 2001, 24 pages.
Luo et al., “c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations,”Blood106(7):2452-2461, Oct. 1, 2005.
Nakamura et al., “Trimethadione Metabolism, A Useful Indicator for Assessing Hepatic Drug-Oxidizing Capacity,”Biochemical Pharmacology47(2):247-251, 1994.
Obrecht et al., “Novel Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding,”Advances in Medicinal Chemistry4:1-68, 1999.
Pelengaris et al., “Minireview. The many faces of c-MYC,”Archives of Biochemistry and Biophysics416:129-136, 2003.
Rendic et al., “Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors,”Drug Metabolism Reviews29(1 & 2):413-580, 1997.
Tumelty et al , “Immobilised, Activated Peptides as Reagents for Cyclic and Derivatised Peptide Libraries,”J. Chem. Soc., Chem. Commun.:1067-1068, 1994.
Arango, D. et al., “c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil in Vitro and in Vivo,”Cancer Research, 61:4910-4915, Jun. 15, 2001.
Batlle, E. et al., “β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB,”Cell, 111:251-263, Oct. 18, 2002.
Behrens, J. et al., “Functional interaction of β-catenin with the transcription factor LEF-1,”Nature, 382:638-642, Aug. 15, 1996.
Bienz and Clevers, “Linking Colorectal Cancer to Wnt Signaling,”Cell, 103:311-320, Oct. 13, 2000.
Blanc-Brude, O. P. et al., “Inhibitor of apoptosis protein survivin regulates vascular injury,”Nature Medicine, 8(9):987-994, Sep. 2002.
Caca, K. et al., “β- and γ-Catenin Mutations, but not E-Cadherin Inactivation, Underlie T-Cell Factor/Lymphoid Enhancer Factor Transcriptional Deregulation in Gastric and Pancreatic Cancer,”Cell Growth&Differentiation, 10:369-376, Jun. 1999.
Cadigan and Nusse, “Wnt signaling: a common theme in animal development,”Genes&Development, 11:3286-3305, 1997.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Cheguillaume, A. et al., “New Potential Monomers for Solid Phase Synthesis of Hydrazinopeptoids: theNα-Substituted-Nβ-Protected Hydrazinoglycines and Hydrazinoglycinals,”Synlett2000, No. 3, pp. 331-334, Mar. 2000.
Chen, S. et al., “Wnt-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor-mediated Transcription,”The Journal of Cell Biology, 152(1):87-96, Jan. 8, 2001.
Chenn and Walsh, “Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors,”Science, 297:365-369, Jul. 19, 2002.
Chrivia, J.C. et al., “Phosphorylated CREB binds specifically to the nuclear protein CBP,”Nature, 365:855-859, Oct. 28, 1993.
Crawford, H.C. et al., “The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors,”Oncogene, 18:2883-2891, 1999.
Daniels, D. L. et al., “β-catenin: molecular plasticity and drug design,”TRENDS in Biochemical Sciences, 26(11):672-678, Nov. 11, 2001.
DasGupta and Fuchs, “Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation,” Development, 126:4557-4568, 1999.
Davis, P.D. et al., “ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature,”Cancer Research, 62:7247-7253, Dec. 15, 2002.
De Ferrari and Inestrosa, “Wnt signaling function in Alzheimer's disease,”Brain Research Reviews, 33:1-12, 2000.
Dermer et al., “Another Anniversary for the War on Cancer,”Bio/Technology12:320, 1994.
Dolle, R.E. “Comprehensive Survey of Combinatorial Library Synthesis: 1999,”Journal of Combinatorial Chemistry, 2(5):383-433, Sep./Oct. 2000.
Dooley and Houghten, “The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands,”Life Sciences, 52(18):1509-1517, 1993.
Dooley, C.T. et al., “Acetalins: Opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries,”Proc. Nat

Affiliated with

Also associated with

Rating

Compounds of reverse turn mimetics and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds of reverse turn mimetics and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds of reverse turn mimetics and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4302968